Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels
02:00pm, Tuesday, 02'nd Mar 2021
Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good buying
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
10:36am, Tuesday, 02'nd Mar 2021
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
Sarepta Therapeutics Drops on Earnings. Why Analysts Remain Hopeful.
08:57am, Tuesday, 02'nd Mar 2021
Sarepta Therapeutics stock fell as markets digested its bigger-than-expected quarterly loss. But analysts say the setup for the stock remains positive.
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
01:07am, Tuesday, 02'nd Mar 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock
Recap: Sarepta Therapeutics Q4 Earnings
04:28pm, Monday, 01'st Mar 2021
Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year to ($1.84
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
04:05pm, Monday, 01'st Mar 2021
– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:12pm, Friday, 26'th Feb 2021
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that we
Earnings Preview: Sarepta Therapeutics
10:16am, Friday, 26'th Feb 2021
Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.
Sarepta stock rises after FDA approves biotech's Duchenne MD treatment
03:48pm, Thursday, 25'th Feb 2021
Shares of Sarepta Therapeutics Inc. rose nearly 1% in late trading Thursday after the biotech company said the U.S. Food and Drug Administration has approved one of its treatments for Duchenne muscula
-- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 24'th Feb 2021
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch
10:00am, Wednesday, 24'th Feb 2021
Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related d
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020
What's in the Cards for Sarepta (SRPT) This Earnings Season?
09:51am, Tuesday, 16'th Feb 2021
Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
